Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.
Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.
Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.
Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.
Apyx Medical (Nasdaq: APYX) priced an underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, representing gross proceeds of approximately $10.0 million. The company granted the underwriter a 45-day option to purchase up to an additional 414,365 shares at the public offering price less underwriting discounts.
The offering is expected to close on or about November 19, 2025, subject to customary closing conditions. Net proceeds are intended for working capital and general corporate purposes. Lucid Capital Markets is sole book-runner. The offering is made under a shelf registration statement declared effective December 2, 2022.
Apyx Medical (Nasdaq: APYX) announced on November 17, 2025 that it has commenced a proposed underwritten public offering of common stock or common stock equivalents, subject to market conditions.
Lucid Capital Markets is sole book-running manager. The offering will be made from a shelf registration on Form S-3 (File No. 333-268532) declared effective December 2, 2022; a preliminary prospectus supplement and prospectus will be filed with the SEC and posted at www.sec.gov when available. The company cautioned there is no assurance the offering will be completed on the anticipated terms.
Company products include Renuvion, AYON Body Contouring System (FDA-cleared), and J-Plasma, supported by more than 90 clinical documents.
Apyx Medical (NASDAQ:APYX) reported Q3 2025 total revenue $12.9M, up from $11.5M a year earlier, driven by Surgical Aesthetics $11.1M (+19%) and domestic sales rising over 30%.
Gross margin improved to 64.4%. Net loss attributable to stockholders narrowed to $2.0M (Q3 2024: $4.7M). Adjusted EBITDA loss fell to $0.1M from $2.4M.
The company launched commercial U.S. sales of the AYON Body Contouring System in September 2025, received 510(k) clearance in May 2025, and filed an additional 510(k) in October 2025 to add power liposuction labeling. Full-year 2025 revenue guidance was raised to $50.5M–$52.5M.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend investor meetings in New York in November 2025.
They will participate in 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at Sheraton NY Times Square, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at Westin NY Grand Central.
Investors seeking meetings should contact their Craig Hallum or Canaccord Genuity representatives. The release also restates the company’s Helium Plasma Platform products (Renuvion, AYON Body Contouring System, J-Plasma), notes >90 clinical documents supporting Renuvion and J-Plasma, and describes AYON as FDA-cleared.
Apyx Medical (NASDAQ: APYX) announced it will release its third quarter fiscal 2025 financial results before markets open on Thursday, November 6, 2025.
Management will host a conference call at 8:00 a.m. Eastern Time on November 6 to discuss results and conduct a Q&A. Dial-in numbers are 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 73607. A live webcast will be available and archived in the company’s Investor Relations section.
Contact for investors is Jeremy Feffer at LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). The company sells helium plasma and RF products under the Renuvion, AYON Body Contouring System, and J-Plasma brands, supported by more than 90 clinical publications.
Apyx Medical (NASDAQ: APYX) announced on October 13, 2025 that it submitted a new FDA 510(k) premarket notification to expand the label of the AYON Body Contouring System to include power liposuction.
The company began a nationwide commercial launch of AYON in September 2025 and said that, if cleared, the power liposuction function could be activated in systems already installed at U.S. surgical centers.
A virtual key opinion leader event on October 14, 2025 will discuss the commercial launch.
Apyx Medical (NASDAQ:APYX) announced a virtual Key Opinion Leader (KOL) event scheduled for October 14, 2025, at 12:00 PM ET. The event will feature Dr. Paul Vanek, Jr., FACS, alongside company management, to discuss the commercial launch of the AYON Body Contouring System™.
The AYON system is the first FDA-cleared all-in-one platform for aesthetic surgical suites, incorporating the company's proprietary Renuvion technology. The system combines fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, designed to streamline procedures and enhance patient outcomes. The event will include formal presentations followed by a Q&A session.
Apyx Medical Corporation (NASDAQ:APYX) has granted a nonstatutory stock option to John Featherstone, the company's Vice President of North American Sales, as part of his employment inducement. The stock option allows for the purchase of 100,000 shares of common stock at an exercise price of $1.85 per share, based on the closing price on August 4, 2025.
The stock option features a four-year vesting schedule, with 25% of shares vesting on the first anniversary and the remainder vesting annually thereafter, contingent upon continued employment. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion® and AYON Body Contouring System™ for cosmetic surgery, and J-Plasma® for hospital surgical applications.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology and manufacturer of Renuvion® and AYON Body Contouring System™, has announced two key executive appointments to strengthen its global sales leadership. John Featherstone joins as Vice President of North American Sales, bringing over 20 years of aesthetics and medical device industry experience. Simon Davies has been appointed as Director of International Sales for Europe and Asia-Pacific, contributing 30 years of global sales leadership expertise.
These strategic hires are aimed at supporting the commercial launch of AYON, the industry's first all-in-one surgical body contouring system, and accelerating the company's global expansion efforts. The appointments align with Apyx's commitment to scaling its commercial operations and enhancing market penetration across key regions.
Apyx Medical (NASDAQ:APYX) reported Q2 2025 financial results with total revenue of $11.4 million, down from $12.1 million year-over-year. The company highlighted the successful launch of its AYON Body Contouring System™ and initiated Renuvion® sales in China.
Key financials include a reduced net loss of $3.8 million (down 42% YoY) and an Adjusted EBITDA loss of $2.0 million (improved 54% YoY). Following strong AYON pre-sales, Apyx increased its FY2025 revenue guidance to $50.0-52.0 million, up from previous guidance of $47.6-49.0 million.
Advanced Energy segment revenue remained relatively flat at $9.7 million, while OEM revenue decreased 28.5% to $1.7 million. The company plans a full commercial launch of AYON in September 2025.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
